EUVIMEDEUVIMED entdecken
Open Access

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

Andrés Muñoz iD, Cihan Ay, Ella Grilz, Sonia López, Carme Font iD, Vanesa Pachón, Victoria Castellón, Virginia Martínez-Marín, Mercedes Salgado, Eva Martínez, Julia Calzas iD, Laura Ortega iD und 4 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.00255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Andrés Muñoz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Thrombosis. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with cancer receiving chemotherapy, but its accuracy in identifying patients at high risk has been questioned. The aim of this study was to develop and validate a clinical-genetic score that improves the assessment of VTE risk in oncology outpatients within 6 months of diagnosis. METHODS The new score was developed using the data of 364 outpatients belonging to the Spanish ONCOTHROMB 12-01 population. In this cohort, clinical data associated with the risk of VTE were collected at the time of diagnosis, including the Khorana score. These patients were also genotyped for the 51 genetic variants known to be associated with VTE. Multivariate logistic regression was performed to determine the weight of each genetic and clinical variable in relation to VTE risk, allowing a clinical-genetic risk score (the ONCOTHROMB score) to be developed. The Khorana and the ONCOTHROMB scores were then compared via the area under the receiver operating characteristic curve (AUC), calibration, and the number of patients needed to treat. The new score was then validated in a study of 263 patients in the Vienna Cancer and Thrombosis Study population. RESULTS Nine genetic variants, tumor site, TNM stage, and a body mass index of > 25 kg/m 2 were found to be associated with VTE and were used to build the ONCOTHROMB score, which better predicted the overall risk of VTE than did the Khorana score (AUC, 0.781 v 0.580; P < .001). Similar AUC results were recorded in the validation study the Vienna Cancer and Thrombosis Study cohort involving patients with the same type of tumor (AUC for the ONCOTHROMB score v the Khorana score: 0.686 v 0.577; P < .001) and with all type of tumors (AUC for the ONCOTHROMB score v the Khorana score: 0.720 v 0.561; P < .0001). CONCLUSION The ONCOTHROMB score for VTE risk in outpatients with cancer, which takes into account both clinical and genetic variables, better identifies patients who might benefit from primary thromboprophylaxis than does the Khorana score.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsThrombosisHumansProspective StudiesAnticoagulantsRisk FactorsRisk Assessment

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Cancer and Thrombosis Working Section, Spanish Society of Medical Oncology (SEOM), Madrid, Spain.
  • Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Genomics of Complex Diseases Unit, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain.
  • Medical Oncology, Hospital Clínic, Barcelona, Spain.

ORCID-Profile: Andrés Muñoz, Carme Font, Julia Calzas, Laura Ortega, Ana Rupérez, Eduardo Salas, Jose Manuel Soria

Zitieren

APA

Muñoz, A., Ay, C., Grilz, E., López, S., Font, C., Pachón, V., Castellón, V., Martínez-Marín, V., Salgado, M., Martínez, E., Calzas, J., Ortega, L., Rupérez, A., Salas, E., Pabinger, I., & Soria, J. M. (2023). A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.00255

Vancouver

Muñoz A, Ay C, Grilz E, López S, Font C, Pachón V, et al. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.00255

BibTeX
@article{Muoz2023,
  author = {Muñoz, Andrés and Ay, Cihan and Grilz, Ella and López, Sonia and Font, Carme and Pachón, Vanesa and Castellón, Victoria and Martínez-Marín, Virginia and Salgado, Mercedes and Martínez, Eva and Calzas, Julia and Ortega, Laura and Rupérez, Ana and Salas, Eduardo and Pabinger, Ingrid and Soria, Jose Manuel},
  title = {A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.00255}
}
Kostenlos starten →